Laurent Essioux

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

Journal: ESMO open

Published: September 01, 2025

Correlation of safety and efficacy of atezolizumab therapy across indications.

Correlation of safety and efficacy of atezolizumab therapy across indications.

Journal: Journal for immunotherapy of cancer

Published: October 18, 2024

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Journal: NPJ digital medicine

Published: February 02, 2024

Baseline risk factors associated with immune related adverse events and atezolizumab.

Baseline risk factors associated with immune related adverse events and atezolizumab.

Journal: Frontiers in oncology

Published: January 05, 2023

Transcriptome signatures from discordant sibling pairs reveal changes in peripheral blood immune cell composition in Autism Spectrum Disorder.

Transcriptome signatures from discordant sibling pairs reveal changes in peripheral blood immune cell composition in Autism Spectrum Disorder.

Journal: Translational psychiatry

Published: September 18, 2019

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.

Journal: Oncotarget

Published: January 11, 2017

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Journal: Clinical and translational science

Published: December 19, 2016

Drug Target Identification and Validation: Global Pharmaceutical Industry Experts on Challenges, Best Strategies, Innovative Precompetitive Collaboration Concepts, and Future Areas of Industry Precompetitive Research and Development.

Drug Target Identification and Validation: Global Pharmaceutical Industry Experts on Challenges, Best Strategies, Innovative Precompetitive Collaboration Concepts, and Future Areas of Industry Precompetitive Research and Development.

Journal: Therapeutic innovation & regulatory science

Published: November 01, 2016

Growth Differentiation Factor-15 and Risk of CKD Progression.

Growth Differentiation Factor-15 and Risk of CKD Progression.

Journal: Journal of the American Society of Nephrology : JASN

Published: August 29, 2016

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects.

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects.

Journal: Nature genetics

Published: April 11, 2016

Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.

Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.

Journal: JAMA neurology

Published: December 15, 2015

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.

Journal: Science translational medicine

Published: December 04, 2015

Showing 1-12 of 21

Last Updated: 09/26/2026